Literature DB >> 34850058

RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Michael Mark1, Roger von Moos1, Richard Cathomas1, Sandro Stoffel2, Silke Gillessen3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34850058      PMCID： PMC9002272          DOI： 10.1093/jnci/djab216

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Authors:  Andrew L Himelstein; Jared C Foster; James L Khatcheressian; John D Roberts; Drew K Seisler; Paul J Novotny; Rui Qin; Ronald S Go; Stephen S Grubbs; Tracey O'Connor; Mario R Velasco; Douglas Weckstein; Ann O'Mara; Charles L Loprinzi; Charles L Shapiro
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

2.  Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

3.  Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

Authors:  Sandro Tiziano Stoffel; Roger von Moos; Beat Thürlimann; Richard Cathomas; Silke Gillessen; Ursina Zürrer-Härdi; Thomas von Briel; Sandro Anchisi; Anita Feller; Corinne Schär; Daniel Dietrich; Matthias Schwenkglenks; Judith E Lupatsch; Michael Thomas Mark
Journal:  Swiss Med Wkly       Date:  2021-03-01       Impact factor: 2.193
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.